Molecular Templates, Inc. MTEM Cash Flow

Molecular templates, inc. (MTEM)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-22,018	-15,881	-38,219	-9,153	-6,168	-6,634	-5,244	-9,695	-8,714	-6,915	-10,967	-4,063	-1,195	-2,564	6,252	-6,864	-7,852	69,713	-6,431	-8,306	-11,154	-5,964	-7,745	-766	-7,109	-7,589	1,176	-12,788	-9,214	28,388	-991	17,001	-115,533	-5,275	-4,125	-7,923	-8,330
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
-	-	-	-	-	-	-	-	72	-	34	19	18	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-257	120	185	249	250	264	239	275	308	336	390	412	430	348	316	340	337	308	23	-	-	-	-
Depreciation, amortization and other
618	554	327	124	177	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88
Stock-based compensation expense
2,192	1,529	1,527	1,443	1,360	1,230	1,197	922	643	362	1,378	26	26	24	-1,560	802	843	2,009	1,476	1,895	1,421	1,556	1,198	1,468	1,266	1,366	1,231	1,272	1,053	923	944	745	398	296	291	203	249
Amortization of debt discount and accretion related to debt
148	139	126	116	105	99	92	64	63	60	12	232	38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in common stock warrant fair value
0	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in common stock warrant fair value
-	-	-	-	-	35	4	297	615	397	-272	5	-2	1	628	-996	370	17,432	315	558	-1,532	1,563	-341	6,665	1,457	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of asset retirement obligations
32	24	23	14	11	11	10	10	8	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of debt
-	-	-	-	-	0	0	0	-115	100	-4,719	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of equipment
0	-	-	0	0	-	-	0	-2	-	-	0	0	-3	-53	60	-9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in common stock warrant value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,379	-5,822	-3,116	-	2,967	19,852	-108,391	-	-	-	-
Changes in operating assets and liabilities:
Prepaid expenses
1,409	-22	82	253	-239	-291	880	178	58	130	253	35	-8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, related party
892	408	0	-295	55	-30,923	30,500	-3,337	4,000	-38	-1,462	750	750	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grants revenue receivable
2,341	-	-	-	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current assets
-	-	-	-	-	-	-	-	71	-45	57	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-293	141	-618	425	338	294	36	120	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right-of-use assets and liabilities
-60	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration receivable/payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144	-1,114	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	385	1,654	-5,255	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-929	-12,902	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,997	-4,105	-8,982	-	1,045	-21,128	37,540	-	-	-	-
Change in common stock warrant value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-939
Prepaid expenses and other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,204	-586	-719	-349	350	337	436	-1,056	-957	1,534	-835	427	-94	751	-5	17	-502	885	223	424	-191	138	-2
Accounts payable
260	128	-338	60	802	-830	1,029	-1,580	-355	-1,409	2,350	407	-139	583	-2,377	1,513	838	289	-199	-1,174	-265	-1,340	523	-1,115	2,317	314	491	-1,470	1,446	169	-256	-312	-1,082	2,084	-173	-126	352
Accrued clinical and development expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,228	-3,509	936	-1,822	-528	2,250	1,856	-3,031	1,681	-1,952	-	-	-	-	-	-	-	-	-	-	-	-
Accrued clinical and development expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,272	1,395	-126	-	2,644	-902	238	1,004	784	-20	258
Accrued liabilities
-3,912	3,873	1,563	476	622	-1,066	605	3,018	110	1,158	-2,471	995	473	224	3,229	-71	-2,582	67	751	-1,745	1,016	483	186	-1,451	801	672	448	-1,049	833	440	380	-579	279	116	306	-16	508
Other current liabilities
-	-	-	-	-	-	-	-	34	-125	145	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
1,746	-36	330	-126	-204	9	-14	31	198	318	-40	40	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities, related party
7,754	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-1,467	23,484	-3,033	-12,676	0	-4,499	27,742	-692	3,585	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue, related party
907	-	-	-	-7,529	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-44	22	22	22	16	56	18	17	14	13	-47	10	7	6	5	5	1	-12	-109	-	-	-	-
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-648	3,498	-1,135	-	-	-	-	-65,875	-3,680	-3,680	-3,681	-3,680	-3,681	-3,680	-3,681	9,288	-3,181	-3,180	27,078	7,979	-1,797	-1,797	57,248	-	-	-	-
Net cash used in operating activities
-18,149	14,028	-16,394	-11,902	-10,976	19,394	-9,723	-5,153	-8,983	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,250	14,867	12,308	-4,742	-6,341	-6,763	-6,005
Cash flows from investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-2,654	-831	6,802	-4,372	-10,627	-7,576	-10,721	-15,865	-3,841	-10,126	-11,158	-10,810	4,359	-9,609	-7,422	-6,302	33,484	-	-	-	-	-	-	-	-
Purchases of property and equipment
938	3,320	5,208	496	625	301	1,231	2,471	1,719	732	349	12	8	-	-	-	-	0	54	17	38	12	41	147	24	52	9	83	14	154	100	194	34	-	-	-	-
Issuance of promissory notes to Molecular Templates, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,959	7,495	10,171	7,143	6,580	32,899	1,636	10,138	10,788	22,349	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
50,463	16,401	18,099	19,071	36,588	10,223	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14,047	28,497	46,407	-	14,836	42,637	17,940	1,748	5,178	15,484	5,744
Increase in other assets
-	-	-	-	-	-	-	-	-	0	140	72	188	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales of marketable securities
18,450	11,501	37,690	9,600	1,293	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,758	2,950	3,285
Net cash used in investing activities
-32,951	-8,220	14,383	-9,967	-35,920	-10,524	-1,231	-2,471	-1,719	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	684	-34,821	-9,482	4,548	1,263	-12,534	-2,459
Cash flows from financing activities:
Proceeds from sales of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,997	1,350	5,020	5,105	3,109	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,461	19,731	13,589	20,727	11,968	18,939	7,163	16,360	16,331	14,024	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,439	17,270	22,088	-	5,020	8,010	8,492	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-196	-293	-18,195	5,563	12,236	3,418	13,530	5,371	-12,001	6,865	11,201	10,501	-5,240	12,764	5,586	-10,310	-24,333	-	-	-	-	-	-	-	-
Payments of capital lease obligations
-	-	-	-	-	-	-	-	13	8	12	12	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of long-term debt and warrants, net
-	-	-	-	-	0	0	0	4,537	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of long-term debt
200	0	0	0	0	0	0	0	3,605	600	600	600	600	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of related party debt
-	-	-	-	-	-	-	-	-	0	0	0	2,685	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from stock option exercises
300	448	453	809	38	126	1	8	148	47	14	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on finance leases
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from promissory note
-	-	-	-	-	-	-	-	-	0	0	2,000	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock and warrants, net of offering expenses
-7	-	-	-	-8	-	-	-	-	-	-	-	-	-1	-12	0	13	38	331	0	28,514	412	4,734	29	345	123	1,424	670	175	464	1,893	2,326	17,227	0	557	-25	29,692
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	4,074	1,208	5,967	0	13	38	331	0	28,514	412	4,734	29	345	123	1,424	670	175	-	-	-	-	-	-	-	-
Net cash provided by financing activities
93	64,375	484	809	30	107	48,051	-4	1,067	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,893	2,326	17,227	0	557	-25	29,692
Net (decrease) increase in cash, cash equivalents, and restricted cash
-51,007	70,183	-1,527	-21,060	-46,866	8,977	37,097	-7,628	-9,635	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash, cash equivalents and restricted cash
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-9,271	63,573	1,668	1,224	84	-5,426	1,191	1,622	-4,120	3,140	-10,494	12,672	-2,849	4,777	-280	-536	3,278	-412	-15,942	9,326	2,395	327	-17,628	20,053	-194	-4,521	-19,322	21,228
Supplemental Cash Flow Information
Cash paid for interest
163	170	170	170	174	343	2	233	51	56	60	66	68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-Cash Investing and Financing Activities
Fixed asset additions in accounts payable and accrued expenses
944	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use asset obtained in exchange for operating lease obligations
0	-	-	-	7,234	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adoption of ASC 842
0	-	-	-	4,179	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total non-cash investing and financing activities
944	-	-	-	11,413	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividends on preferred stock
-	-	-	-	-	-	-	-	-	0	138	392	428	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in unrealized gain (loss) in marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	8	-7	1	-4